Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
315.5 INR | +2.45% | +3.19% | +26.38% |
07:14am | US FDA Approves Samsung Bioepis' Eye Disease Drug Opuviz | MT |
May. 17 | Jefferies Adjusts Biocon’s Price Target to INR230 From INR250, Keeps at Underperform | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.38% | 4.42B | |
+10.41% | 115B | |
+11.49% | 106B | |
-5.85% | 24.69B | |
-1.51% | 21.97B | |
-5.15% | 19.27B | |
-11.49% | 17.56B | |
-39.36% | 17.32B | |
+5.44% | 14.03B | |
+33.50% | 12.13B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon Begins Phase-2 Clinical Trial of Itolizumab for Ulcerative Colitis